Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesis

Adeline Rosu, Najla El Hachem, Francesca Rapino, Kevin Rouault-Pierre, Joseph Jorssen, Joan Somja, Eve Ramery, Marc Thiry, Laurent Nguyen, Maarten Jacquemyn, Dirk Daelemans, Christopher M. Adams, Dominique Bonnet, Alain Chariot, Pierre Close, Fabrice Bureau, Christophe J. Desmet

Research output: Contribution to journalArticlepeer-review


The hematopoietic system is highly sensitive to perturbations in the translational machinery, of which an emerging level of regulation lies in the epitranscriptomic modification of transfer RNAs (tRNAs). Here, we interrogate the role of tRNA anticodon modifications in hematopoiesis by using mouse models of conditional inactivation of Elp3, the catalytic subunit of Elongator that modifies wobble uridine in specific tRNAs. Loss of Elp3 causes bone marrow failure by inducing death in committing progenitors and compromises the grafting activity of hematopoietic stem cells. Mechanistically, Elp3 deficiency activates a p53-dependent checkpoint in what resembles a misguided amino acid deprivation response that is accompanied by Atf4 overactivation and increased protein synthesis. While deletion of p53 rescues hematopoiesis, loss of Elp3 prompts the development of p53-mutated leukemia/lymphoma, and inactivation of p53 and Elongator cooperatively promotes tumorigenesis. Specific tRNA-modifying enzymes thus condition differentiation and antitumor fate decisions in hematopoietic stem cells and progenitors.

Original languageEnglish (US)
Article number20200662
JournalJournal of Experimental Medicine
Issue number3
StatePublished - 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesis'. Together they form a unique fingerprint.

Cite this